The primary mission of NB BioSciences is to accelerate the development of effective diagnostics and therapies for neurodegenerative diseases. We do this be developing in house innovative technologies and solutions, but also by deploying our expertise, technologies and platforms to support the advancement of promising targets of our partners and clients. Our ultimate goal is to create collaborations and synergies that will lead to better treatment options for patients suffering from neurodegenerative diseases. We will not spare any effort to achieve this goal. 

Characterization and validation of discovery tools, imaging agents and therapeutic drugs and antibodies.

ND BioScience leverages an in-depth understanding of the physiological and pathological diversity of proteins linked to neurodegenerative diseases to prepare comprehensive libraries of pure proteins that reconstitute the complexity of monomeric and aggregated forms of each protein. These libraries represent powerful platforms for the discovery of novel targets and the characterization and validation of both research tools, PET tracers and therapeutic drugs and antibodies.

Before you invest in the next antibody drug, let us help you make a well-informed investment”

Anti-aggregation properties and mode of action of promising drugs.

ND BioSciences has developed an integrated platform the enables comprehensive assessment of not only the anti-aggregation properties of small molecules, peptides or proteins, but also their mode of action. Using a set of well validated quantitative assays, we can determine the inhibitory potency and at which stages along the amyloid formation pathway does your molecule of interest act on. We can also assess the therapeutic potential of your molecule against one protein or several proteins linked to neurodegenerative diseases (e.g. Alpha-Synuclein, Tau and Tau isoforms, TDP-43, Huntingtin proteins, Abeta).

Efficacy and mode of action of promising Parkinson’s disease drugs using our integrated cell-based assays of Alpha-Synuclein toxicity, aggregation and LB formation.

At ND BioSciences, we employ a series of well-characterized and validated cell-based assays that enable us to interrogate the different key steps involved in the formation of pathological aSyn aggregates, from misfolding to seeding to fibrillization and to the formation of Lewy-body and GCI-like inclusions. Our platforms provide opportunities to investigate the relationship between these various steps and mechanisms that drive neurodegeneration in Parkinson’s disease and to assess how specific targets or drug-candidates influence aSyn pathology and neurotoxicity.   

Development and validation of special tools, standards and assays.

ND BioSciences is committed to deploying its extensive expertise and unique capabilities to develop and validate novel tools that are essential to advancing translational research and drug discovery in neurodegenerative diseases.